Aug 2026· AMB Express· Vol 16· 0 citations· 72 references
Medicine
TL;DR
The findings highlight the potential of phycobiliprotein-based synergistic formulations as promising candidates for the development of safe and effective anti-HIV-1 therapeutics.
Abstract
Human immunodeficiency virus type 1 (HIV-1) remains a major global public health challenge due to lifelong persistence, latency, and the emergence of drug resistance. Natural bioactive compounds are increasingly being explored as alternative or adjunct antiviral strategies. In this study, we evaluated the antiviral efficacy and cytotoxicity of a synergistic pharmaceutical composition comprising three phycobiliproteins: C-phycocyanin (C-PC), B-phycoerythrin (B-PE), and allophycocyanin (APC), derived from cyanobacteria and marine algae. Individual and combinatorial effects were assessed against HIV-1 using TZM-bl cells and peripheral blood mononuclear cells (PBMCs). A Box–Behnken experimental design was employed to identify optimal synergistic ratios. Among fifteen combinations initially screened at a fixed concentration of 50 µg/mL, five exhibited strong antiviral activity. The optimized formulation (CBA: C2; 73.28% C-PC, 20.70% B-PE, and 6.02% APC) produced up to ~ 100% inhibition of HIV-1 during the screening assay. Subsequent dose-response analyses demonstrated IC50 values ranging from 5.01 to 12.60 µg/mL across different antiviral assays, while exhibiting minimal cytotoxicity (CC50: 577.56 ± 34.5 µg/mL in TZM-bl cells and 247.64 ± 25.49 µg/mL in PBMCs). The formulation showed a high selectivity index, indicating a favourable therapeutic window. These findings highlight the potential of phycobiliprotein-based synergistic formulations as promising candidates for the development of safe and effective anti-HIV-1 therapeutics.
This study systematically characterizes SSB2’s dual-stage anti-PEDV profile and its broad-spectrum activity against spike-mutant strains, supporting SSB2 as a promising herbal lead for developing veterinary antivirals targeting variant PEDV.
Han Zhang, Yue Liu, Fan Zhang et al.· Viruses· 0 citations
Dengue virus (DENV) remains a major global health threat, particularly in tropical and subtropical regions, due to the lack of effective antiviral therapies. In this study, we evaluated a novel combination strategy using melittin, a bee venom-derived antiviral peptide, together with Clinacanthus nutans extract to enhan...
Natthanich Boonsatit, Somluethai Fungfueang, Saruda Thongyim et al.· International Journal of Mol...· 0 citations
The newly developed carvacrol–DABCO amphiphilic hybrids represent a promising class of multitarget antibacterial agents and their broad-spectrum efficacy, bactericidal kinetics, RNA-cleaving activity, low hemolytic toxicity, and favorable selectivity indices support their potential for further in vivo evaluation.
D. Zadvornykh, Mei-Ling Wang, A. Bardasheva et al.· Antibiotics· 0 citations
Natural products remain indispensable scaffolds in antiviral drug discovery, particularly against high-burden viral pathogens. In this study, two major sesquiterpene lactones, dehydrocostus lactone (1) and costunolide (2), were isolated from Laurus nobilis L. leaves and evaluated for their antiviral potential against h...
Yhiya M. Amen, Marwa Elsbaey, George Mpekoulis et al.· Viruses· 0 citations
In recent years, following the COVID-19 pandemic, the emergence of antibiotic-resistant microorganisms has increased. This surge has prompted global research into new biologically active molecules, particularly those focused on combination therapies involving antifungal agents. Synthetic antimicrobial peptides have eme...
T. A. M. Souza, Érica de O. Mello, F. Trindade et al.· Current Microbiology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.